US Pharma MarketingSpeciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing
Speciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
GlobalData’s Drugs By Manufacturer Database reveals the top four CDMOs for innovator and biosimilar HPAPI contract manufacturing.
Source: Pharmaceutical Technology